Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2019

01.06.2019 | editorial

Saving lives with lung cancer screening

verfasst von: Prim. Univ.-Prof. Dr. Wolfgang Hilbe, PD Dr. med. univ. Andreas Pircher

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Lung cancer is the number one reason for cancer-related death in Austria and many other countries, especially due the fact that the majority of patients are diagnosed at an advanced stage of the disease. Two large trials (NLST and NELSON) proved the efficacy of low-dose CT (LD-CT) for lung cancer screening [ 1, 2]. Lung cancer deaths were decreased and early diagnosis facilitated curative treatment options. Thus, the risk to die from lung cancer was reduced by 26% in the NELSON trial. …
Literatur
1.
Zurück zum Zitat National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. CrossRef National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. CrossRef
2.
Zurück zum Zitat De Koning H, Van Der Aalst C, Ten Haaf K, Oudkerk M. PL02.05 effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. J Thorac Oncol. 2018;13(10):185. CrossRef De Koning H, Van Der Aalst C, Ten Haaf K, Oudkerk M. PL02.05 effects of volume CT lung cancer screening: mortality results of the NELSON randomised-controlled population based trial. J Thorac Oncol. 2018;13(10):185. CrossRef
Metadaten
Titel
Saving lives with lung cancer screening
verfasst von
Prim. Univ.-Prof. Dr. Wolfgang Hilbe
PD Dr. med. univ. Andreas Pircher
Publikationsdatum
01.06.2019
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2019
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0496-3

Weitere Artikel der Ausgabe 2/2019

memo - Magazine of European Medical Oncology 2/2019 Zur Ausgabe